GlassScriptPhysician profile
Keith Radbill
NPI 1861557795
$12,355.16
in general payments reported to CMS, 2019-2025
22 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $66.41 · 2021: $23.61 · 2022: $41.92 · 2023: $204 · 2024: $593 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,640 · Food and Beverage: $1,772 · Consulting Fee: $900 · Travel and Lodging: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,640.00 |
| Food and Beverage | $1,772.03 |
| Consulting Fee | $900.00 |
| Travel and Lodging | $409.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $10,369.04 | 2023-2025 | Vivitrol, Vivitrol |
| Gilead Sciences, INC. | $497.29 | 2023-2025 | Epclusa |
| Braeburn INC. | $412.73 | 2023-2025 | Brixadi |
| Indivior INC. | $265.53 | 2024-2025 | Sublocade |
| Nevro Corp. | $213.84 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.90 | 2019-2020 | |
| Orexo US, INC. | $82.95 | 2022-2024 | Zubsolv |
| Uswm, LLC | $51.97 | 2021-2022 | |
| Lilly USA, LLC | $47.68 | 2019-2020 | |
| Pacira Therapeutics, INC. | $38.87 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $38.54 | 2025 | Rexulti |
| Novo Nordisk INC | $36.69 | 2024 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $35.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.15 | 2019-2020 | |
| Boston Scientific Corporation | $22.80 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.94 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.70 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $14.31 | 2019 | |
| Kaleo, INC. | $13.79 | 2019 | |
| Mdd US Operations, LLC | $13.50 | 2019 | |
| Shionogi INC | $13.13 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Radbill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.